Abstract：
Introduction: It has been demonstrated the dysregulation of the cardiac endocannabinoid system in cardiovascular diseases. Thus, the modulation of this system through the administration of phytocannabinoids present in medicinal cannabis oil (CO) emerges as a promising therapeutic approach. Furthermore, phytocannabinoids exhibit potent antioxidant properties, making them highly desirable in the treatment of cardiac pathologies, such as hypertension-induced cardiac hypertrophy (CH). Objective: To evaluate the effect of CO treatment on hypertrophy and mitochondrial status in spontaneously hypertensive rat (SHR) hearts. Methods: Three-month-old male SHR were randomly assigned to CO or olive oil (vehicle) oral treatment for 1 month. We evaluated cardiac mass and histology, mitochondrial dynamics, membrane potential, area and density, myocardial reactive oxygen species (ROS) production, superoxide dismutase (SOD), and citrate synthase (CS) activity and expression. Data are presented as mean ± SEM (n) and compared by t-test, or two-way ANOVA and Bonferroni post hoc test were used as appropriate. p < 0.05 was considered statistically significant. Results: CH was reduced by CO treatment, as indicated by the left ventricular weight/tibia length ratio, left ventricular mass index, myocyte cross-sectional area, and left ventricle collagen volume fraction. The ejection fraction was preserved in the CO-treated group despite the persistence of elevated systolic blood pressure and the reduction in CH. Mitochondrial membrane potential was improved and mitochondrial biogenesis, dynamics, area, and density were all increased by treatment. Moreover, the activity and expression of the CS were enhanced by treatment, whereas ROS production was decreased and the antioxidant activity of SOD increased by CO administration. Conclusion: Based on the mentioned results, we propose that 1-month oral treatment with CO is effective to reduce hypertrophy, improve the mitochondrial pool and increase the antioxidant capacity in SHR hearts.
摘要：
简介：已证明心脏内源性大麻素系统在心血管疾病中的失调。因此，通过施用药用大麻油（CO）中存在的植物大麻素来调节该系统成为一种有前途的治疗方法。此外，植物大麻素表现出有效的抗氧化特性，使它们在心脏病的治疗中非常受欢迎，如高血压引起的心脏肥大（CH）。目的:评价CO治疗对自发性高血压大鼠(SHR)心肌肥厚和线粒体状态的影响。方法：将3个月大的男性SHR随机分配到CO或橄榄油（载体）口服治疗1个月。我们评估了心脏质量和组织学，线粒体动力学，膜电位，面积和密度，心肌活性氧（ROS）的产生，超氧化物歧化酶（SOD），和柠檬酸合酶(CS)活性和表达。数据以平均值±SEM(n)表示，并通过t检验进行比较。或使用双向方差分析和Bonferroni事后检验。p<0.05被认为是统计学上显著的。结果：CO治疗降低了CH，如左心室重量/胫骨长度比所示，左心室质量指数,心肌细胞横截面积，和左心室胶原体积分数。尽管收缩压持续升高和CH减少，但CO治疗组的射血分数仍得到保留。线粒体膜电位得到改善，线粒体生物发生，动力学,area,和密度都增加了治疗。此外，通过处理增强了CS的活性和表达，而通过CO给药，ROS的产生减少，SOD的抗氧化活性增加。结论：基于上述结果，我们建议用CO口服治疗1个月可有效减少肥大，改善线粒体库并增加SHR心脏的抗氧化能力。
